<DOC>
	<DOCNO>NCT00036270</DOCNO>
	<brief_summary>To compare effect exemestane 5 year versus tamoxifen exemestane give sequentially 5 year adjuvant treatment postmenopausal woman early breast cancer . This Pfizer sponsor trial part international collaboration investigator conduct 7 similar yet independent study 9 country . This study design part large TEAM trial data 7 study combine . A pre-specified analysis pool data conduct .</brief_summary>
	<brief_title>Randomized Phase III Study Of Exemestane ( Aromasin ) For 5 Years Versus Tamoxifen 2.5 3 Years Followed By Exemestane</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically/cytologically confirm adenocarcinoma breast , follow adequate surgical resection and/or radiotherapy , and/or adjuvant chemotherapy , indicate . Stage T13 N02 Mo , Any TNM stage BC adjuvant hormonal therapy consider . Those patient deem potentially curative primary surgical treatment one follow criterion : Inflammatory breast cancer Histologically positive supraclavicular node Ulceration/infiltration local skin metastasis Neoadjuvant chemotherapy Ductal carcinoma situ ( DCIS ) lobular carcinoma situ ( LCIS ) without invasion ER PR negative primary tumor ER/PR unknown status .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>